Pharvaris N.V. Files September 2024 6-K Report

TL;DR

Pharvaris N.V. (PHVS) filed its monthly 6-K report on 9/25/24, confirming its reporting status.

AI Summary

Pharvaris N.V. filed a Form 6-K on September 25, 2024, reporting for the month of September 2024. The company, previously known as Pharvaris, B.V., is incorporated in P7 and has its principal executive office in Leiden, The Netherlands. This filing is made under the Securities Exchange Act of 1934 and indicates that Pharvaris N.V. files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Pharvaris N.V.'s ongoing compliance and reporting status.

Risk Assessment

Risk Level: low — This is a routine 6-K filing that does not contain new material financial information or significant operational updates.

Key Numbers

• 001-40010 — SEC File Number (Identifies the company's registration with the SEC)

Key Players & Entities

• Pharvaris N.V. (company) — Filer of the 6-K report
• Pharvaris, B.V. (company) — Former name of the registrant
• 001-40010 (dollar_amount) — SEC file number
• 20240925 (date) — Filing date

FAQ

From the Filing

0000950170-24-109195.txt : 20240925 0000950170-24-109195.hdr.sgml : 20240925 20240925065002 ACCESSION NUMBER: 0000950170-24-109195 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240925 FILED AS OF DATE: 20240925 DATE AS OF CHANGE: 20240925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241321265 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 6-k_september_25.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. PHARVARIS N.V.   Effective October 4, 2024, Morgan Conn, Ph.D., Chief Business Officer of Pharvaris N.V. (the “Company”), voluntarily resigned to pursue another opportunity. Dr. Conn’s resignation is not due to any disagreement with the Company. Dr. Conn’s responsibilities will be divided and reassigned to the Company’s current executive committee members. The information included in this Form 6-K is hereby incorporated by reference into the Company’s registration statements on Form F-3 (Registration Numbers 333-278650, 333-277705 and 333-273757) and Form S-8 (Registration Number 333-252897).     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   PHARVARIS N.V.     Date: September 25, 2024 By: /s/ Berndt Modig   Name: Berndt Modig   Title: Chief Executive Officer